Home>>Signaling Pathways>> Cell Cycle/Checkpoint>> c-Myc>>Lusianthridin

Lusianthridin

Catalog No.GC61014

Lusianthridin, a pure compound from Dendrobium venustum, have an anti-migratory effect. Lusianthridin enhances c-Myc degradation through the inhibition of Src-STAT3 signaling.

Products are for research use only. Not for human use. We do not sell to patients.

Lusianthridin Chemical Structure

Cas No.: 87530-30-1

Size Price Stock Qty
5mg
$1,066.00
In stock
10mg
$1,715.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Lusianthridin, a pure compound from Dendrobium venustum, have an anti-migratory effect. Lusianthridin enhances c-Myc degradation through the inhibition of Src-STAT3 signaling[1].

Lusianthridin (0-100 μM) inhibits cell viability at concentrations greater than 50 μM in both H460 and H292 cells[1].Lusianthridin significantly reduces the CSC populations in both H460 and H292 cells of the CSC spheres, with a significant decrease in the size of the H460 CSC spheres by approximately 10%, 63%, and 77% at day 3 at concentration 5, 10, and 20 μM Lusianthridin, respectively[1]. Cell Viability Assay[1] Cell Line: The human non-small cell lung cancer cell lines, NCI-H460, and NCI-H292 cells[1].0-100 μM.

[1]. Narumol Bhummaphan, et al. Targeting of Lung Cancer Stem Cells via Src-STAT3 Suppression. Phytomedicine. 2019 Sep;62:152932.

Reviews

Review for Lusianthridin

Average Rating: 5 ★★★★★ (Based on Reviews and 22 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Lusianthridin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.